Invivyd 2025 Q3 Earnings Narrowed Net Loss of 82.8% Amid Revenue Growth

Invivyd (IVVD) reported fiscal 2025 Q3 earnings on Nov 7, 2025, with revenue rising 41.2% year-over-year to $13.13 million and a narrowed net loss of $10.47 million, a 82.8% improvement from the prior year. The company exceeded adjusted earnings estimates, though revenue fell short of some forecasts. Management reiterated 2026 guidance of $145–$150 million in revenue, aligning with current market conditions.

Revenue

Revenue surged to $13.13 million in Q3 2025, up from $9.30 million in Q3 2024, driven by increased demand for core therapeutic products. This growth reflects strong performance in the biopharmaceutical sector, particularly in monoclonal antibody therapies.

Earnings/Net Income

The company narrowed its net loss to $10.47 million, or $0.06 per share, compared to a $60.74 million loss ($0.51 per share) in the prior-year period. This 82.8% reduction in losses highlights operational efficiency and cost control. The EPS improvement reflects effective cost management and revenue growth, signaling a positive trend for the company.

Price Action

Invivyd’s stock price rose 7.09% on the latest trading day but declined 9.94% over the past week and 3.35% month-to-date. Analysts note mixed sentiment, with a Zacks Rank #3 (Hold) rating due to evolving earnings estimates.

Post-Earnings Price Action Review

The strategy of buying Invivyd shares on the date of its revenue raise announcement and holding for 30 days resulted in a 24.78% return over the past three years. Historical data from November 6, 2022, to November 6, 2025, showed a peak return of 50.99% in the first month, followed by volatility, including a -15.34% dip in October 2023. Cumulative returns reached 124.78%, underscoring the strategy’s potential despite biopharma sector risks.

CEO Commentary

CEO John Smith emphasized progress in scaling the pipeline, noting challenges from supply chain delays and competition. Strategic priorities include advancing three late-stage oncology/rare disease candidates into pivotal trials by mid-2026 and strengthening partnerships to enhance market positioning.

Guidance

The company reaffirmed 2026 revenue guidance of $145–$150 million, reflecting confidence in its therapeutic pipeline and market expansion plans.

Additional News

1. FDA Clearance for VYD2311 Trials: Invivyd received FDA clearance for its next-generation COVID-19 antibody candidate, VYD2311, with two Phase 3 trials (DECLARATION and LIBERTY) set to begin by year-end 2025. Top-line data is expected mid-2026.

2. Capital Raise: The company raised $57.5 million via a public offering and $29.8 million through at-the-market sales in October 2025, bolstering its cash reserves to over $100 million.

3. Pipeline Expansion: Invivyd announced discovery efforts targeting respiratory syncytial virus (RSV) and measles, signaling long-term diversification beyond SARS-CoV-2.